Skip to main content
. 2023 Apr 4;41(20):3247–3257. doi: 10.1016/j.vaccine.2023.03.065

Fig. 1.

Fig. 1

A and B. Proportion of participants with positive antibody response defined as postvaccination antibody levels over the cut-off (seropositivity) in seronegative patients or ≥ 4-fold increase in antibody levels in patients with seropositivity for both spike antigens in each treatment group (biologic/ts DMARD as monotherapy or biologic/ts DMARD + csDMARD; B Biologic/ts DMARDs all) and controls.